BWXT wants to buy back $800 million of bonds. What do holders give up?
The nuclear supplier's refinancing could strip restrictions from bonds that stay outstanding. The funding terms explain what would still back their payments.
BWX Technologies wants to replace $800 million of bonds due in 2028 and 2029 with a proposed $500 million issue due in 2034, plus cash. Alongside the purchases, it is asking bondholders to approve changes that would give the nuclear supplier more financial freedom.
Those changes could also affect investors who keep their bonds. The proposal removes restrictions on borrowing, dividends, asset sales and other corporate actions, while making it easier to release the subsidiary guarantees, which are promises by group companies to back the debt, through a funded trust.
Selling a bond also delivers a vote
BWXT is offering to buy any or all of two $400 million bond series, each paying 4.125% annual interest. Investors who tender their bonds also consent to the proposed changes. A majority of the outstanding principal in each series is needed to approve that series' amendments.
If approved and made operative through payment for the tendered bonds, the changes would bind the investors who did not sell as well. They would lose substantially all the old restrictions and some related default protections. Principal and interest payment obligations would remain.
The funding requirement behind the release
Research by Ticker Byline shows that BWXT's proposed changes leave the old agreements' trust-funding requirements in place. To release the guarantees through the planned process, BWXT would have to place enough cash or government securities in trust to cover the remaining principal, any premium and interest. The proposed amendments widen the timing window for that process without removing its funding clause.
The original agreements allow BWXT to end the old debt contracts by funding that trust when the bonds mature or are to be redeemed within one year. BWXT wants that window extended to two years for the 2028 bonds and three years for the 2029 bonds. That would allow it to complete the process sooner and release the subsidiary guarantees.
There is also an existing route if the votes fall short. BWXT says it would seek covenant defeasance, which removes specified restrictions and guarantees after funding the trust and meeting the agreements' other conditions. Investors would continue receiving interest and principal on the scheduled dates.
More flexibility as the business grows
The new $500 million issue is smaller than the face value of the old bonds. BWXT plans to add cash to pay for the repurchases, fund the remaining bonds and cover expenses. The November 4 announcement did not specify the new bonds' coupon.
It ended September with $568.5 million in cash and equivalents and $2.022 billion of debt at its accounting carrying value. A separate revolving bank line had no borrowings and about $1.249 billion available at that date. On November 3, BWXT extended that $1.25 billion facility's maturity by one year to November 10, 2031.
The balance sheet supports a business with growing funding needs. Our earlier earnings analysis explains why BWXT expects stronger 2027 profit growth but little cash-flow growth: contract delivery and capital spending absorb cash. The announced medical-business sale, valued at up to $800 million, remained pending in the latest disclosures.
The tender prices are scheduled to be set on November 10 at 3 p.m. New York time, with the offers due to expire two hours later. BWXT expects settlement on November 13. The refinancing would reset both the repayment timetable and the conditions attached to debt left behind.